Clinical Design and Timeline

The NCT07156227 trial, sponsored by the U.S. National Cancer Institute (NCI) and conducted by the UPMC Hillman Cancer Center, is a Phase 1 dose-escalation and expansion study targeting recurrent or newly diagnosed head and neck squamous cell carcinoma (HNSCC). It will enroll 39 adults with tumors that have recurred in previously irradiated areas and are not amenable to surgical resection. The study will evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of camonsertib in combination with stereotactic body radiation therapy (SBRT) re-irradiation. The trial status is Recruiting, with an estimated start date of February 13, 2027, and primary and overall completion dates set for May 31, 2029. Efficacy endpoints include objective response rate (ORR) and progression-free survival (PFS) within the irradiation field, serving as early signals for further development.

Rationale for Combination of Drug and Radiation

Camonsertib (RP-3500), currently under non-branded development by Repare Therapeutics, is an oral ATR (ataxia telangiectasia and Rad3-related protein) kinase inhibitor. ATR is a key enzyme in responding to replication stress and DNA damage; its inhibition hinders cancer cells from repairing radiation-induced DNA damage, thereby increasing radiosensitivity. Patients will receive SBRT in 4–5 fractions over 3 weeks, with camonsertib administered on the day of and the day after each radiation session, using an intermittent dosing strategy to limit normal tissue exposure and systemic toxicity. Biomarker-based patient selection will also assess ATM·TP53 mutations, HPV status, tumor mutation burden, and circulating tumor DNA.

Treatment Landscape and Competitive Position

The standard systemic therapy for recurrent/metastatic HNSCC is Merck & Co. (MRK)'s Keytruda (pembrolizumab, PD-1) as monotherapy or in combination with platinum-based and 5-FU regimens, with FDA approval for first-line treatment granted on June 10, 2019. Bristol Myers Squibb (BMY)'s Opdivo (nivolumab, PD-1) and Eli Lilly (LLY)'s Erbitux (cetuximab, EGFR) are also key options, with Erbitux receiving HNSCC approval on March 1, 2006. This trial targets a narrower, high-medical-need area—local salvage therapy for previously irradiated sites—rather than competing in the broader systemic immunotherapy space. In the ATR class, AstraZeneca (AZN)'s ceralasertib, Bayer's elimusertib, and Merck KGaA's berzosertib are in clinical competition.

Market Potential and Rights Structure

The global HNSCC treatment market is projected to grow from approximately USD 2.49 billion in 2025 to USD 4.09 billion in 2031, with North America as the largest region. Camonsertib, as a Phase 1 investigational drug, has no history of FDA, EMA, or PMDA marketing approvals or advisory committee (AdComm) meetings. Roche secured global rights in 2022, agreeing to an upfront payment of USD 125 million, potential milestones up to USD 1.2 billion, and royalties in the mid-to-high single digits. However, the partnership was terminated on May 7, 2024, and Repare regained rights. Thus, this NCI-sponsored study represents a non-dilutive clinical option to validate the radiation combination value and enhance the asset’s potential for licensing, using limited company capital.